PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
June 3, 2026Nature MedicineOpen Access

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

LBLauren Averett ByersBCByoung Chul ChoACAlissa J. Cooper

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates safety and efficacy of ABBV-706 in relapsed/refractory small cell lung cancer, highlighting promising outcomes.

Key Points

  • This trial aims to evaluate the safety and efficacy of ABBV-706 in patients with advanced small cell lung cancer and other solid tumors.
  • Open-label, phase 1 trial with 288 patients receiving ABBV-706 Q3W; 240 on monotherapy, 124 with R/R SCLC.
  • Dose escalation and optimization focused on safety, pharmacokinetics, and antitumor activity.
  • Primary endpoints included safety and the determination of recommended phase 2 dose.
  • ABBV-706 demonstrated an objective response rate of 52% in R/R SCLC (65/124).
  • Treatment-related adverse events occurred in 93% of the R/R SCLC cohort, with grade 3 or higher in 61%.
  • Median overall survival was 12.4 months at the RP2D of 1.8 mg kg−1.

Cite This Study

Byers et al. (2026) studied this question.

synapsesocial.com/papers/6a1fc696dee9eb8c0dce79b2https://doi.org/10.1038/s41591-026-04452-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.2024 · 31 citations
  2. 2SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer2026
  3. 3Abstract 3148: ABBV-706 is a novel SEZ6-targeted topoisomerase 1 inhibitor ADC for SCLC and other neuroendocrine cancers2024 · 4 citations
  4. 4SEZanne: A phase 2 randomized, open-label, multicenter study to evaluate the optimal dose, safety, and efficacy of ABBV-706 in combination with atezolizumab (atezo) versus standard of care (SOC) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC).2026
  5. 5Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial2026